200 related articles for article (PubMed ID: 27021324)
1. Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.
Zhang H; Nguyen MH; Clancy CJ; Joshi R; Zhao W; Ensor C; Venkataramanan R; Shields RK
Antimicrob Agents Chemother; 2016 Jun; 60(6):3558-62. PubMed ID: 27021324
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole Tablets in Real-Life Lung Transplantation: Impact on Exposure, Drug-Drug Interactions, and Drug Management in Lung Transplant Patients, Including Those with Cystic Fibrosis.
Launay M; Roux A; Beaumont L; Douvry B; Lecuyer L; Douez E; Picard C; Grenet D; Jullien V; Boussaud V; Guillemain R; Billaud EM
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311077
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.
Petitcollin A; Boglione-Kerrien C; Tron C; Nimubona S; Lalanne S; Lemaitre F; Bellissant E; Verdier MC
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848009
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.
Han K; Capitano B; Bies R; Potoski BA; Husain S; Gilbert S; Paterson DL; McCurry K; Venkataramanan R
Antimicrob Agents Chemother; 2010 Oct; 54(10):4424-31. PubMed ID: 20679503
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
Gubbins PO; Krishna G; Sansone-Parsons A; Penzak SR; Dong L; Martinho M; Anaissie EJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):1993-9. PubMed ID: 16723557
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole liquid vs tablet formulation in lung transplant recipients.
Stelzer D; Weber A; Ihle F; Matthes S; Ceelen F; Zimmermann G; Kneidinger N; Schramm R; Winter H; Zoller M; Vogeser M; Behr J; Neurohr C
Mycoses; 2018 Mar; 61(3):186-194. PubMed ID: 29110351
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
9. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients.
Thakuria L; Packwood K; Firouzi A; Rogers P; Soresi S; Habibi-Parker K; Lyster H; Zych B; Garcia-Saez D; Mohite P; Patil N; Sabashnikov A; Capoccia M; Chibvuri M; Lamba H; Tate H; Carby M; Simon A; Leaver N; Reed A
Int J Antimicrob Agents; 2016 Jan; 47(1):69-76. PubMed ID: 26607341
[TBL] [Abstract][Full Text] [Related]
12. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
Prattes J; Duettmann W; Hoenigl M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5595-9. PubMed ID: 27324763
[TBL] [Abstract][Full Text] [Related]
16. Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients.
Kozuch JM; Feist A; Yung G; Awdishu L; Hays S; Singer JP; Florez R
Clin Transplant; 2018 Aug; 32(8):e13300. PubMed ID: 29806967
[TBL] [Abstract][Full Text] [Related]
17. Isavuconazole pharmacokinetics in a patient with cystic fibrosis following bilateral orthotopic lung transplantation.
Kabulski GM; MacVane SH
Transpl Infect Dis; 2018 Jun; 20(3):e12878. PubMed ID: 29512930
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
[TBL] [Abstract][Full Text] [Related]
19. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.
Pham AN; Bubalo JS; Lewis JS
Mycoses; 2016 Apr; 59(4):226-233. PubMed ID: 26742659
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
